Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.

@article{Nguyn2008ChemicalTO,
  title={Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.},
  author={Thi Li{\^e}n-Anh Nguy{\^e}n and Hesham Abdelbary and Meztli D Arguello and Caroline J. Breitbach and Simon Leveille and Jean-Simon Diallo and Amber Yasmeen and Tarek A. Bismar and David H. Kirn and Theresa Falls and Valerie E Snoulten and Barbara C Vanderhyden and Joel A Werier and Harold L. Atkins and Markus V{\"a}h{\"a}-Koskela and David Francis Stojdl and John Cameron Bell and John Hiscott},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2008},
  volume={105 39},
  pages={14981-6}
}
Intratumoral innate immunity can play a significant role in blocking the effective therapeutic spread of a number of oncolytic viruses (OVs). Histone deacetylase inhibitors (HDIs) are known to influence epigenetic modifications of chromatin and can blunt the cellular antiviral response. We reasoned that pretreatment of tumors with HDIs could enhance the replication and spread of OVs within malignancies. Here, we show that HDIs markedly enhance the spread of vesicular stomatitis virus (VSV) in a… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 73 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 51 references

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

  • P Richardson
  • Leuk Lymphoma
  • 2008

Antitumor activity of the histone deacetylase inhibitor MS - 275 in prostate cancer models

  • DZ Qian
  • 2007

Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer

  • DZ Qian
  • 2007

Similar Papers

Loading similar papers…